Cost-effectiveness of atypical antipsychotic medications versus conventional medication

Bibliography

• KESSLER RC, BIRNBAUM H, DEMLER O et al.: The prevalence and correlates of nonaffective psychosis in the National Comorbidity Survey Replication (NCS-R). Biol. Psychiatry (2005) 58(8):668-676.
   PubMed Web of Science ®Google Scholar
• WU EQ, BIRNBAUM HG, SHI L et al.: The economic burden of schizophrenia in the United States in 2002. J. Clin. Psychiatry (2005) 66(9):1122-1129.
   PubMed Web of Science ®Google Scholar
• PALMER BA, PANKRATZ VS, BOSTWICK JM: The lifetime risk of suicide in schizophrenia: a reexamination. Arch. Gen. Psychiatry. (2005) 62(3):247-253.
   PubMed Web of Science ®Google Scholar
• SUSSER E, LIN SP, CONOVER S: Risk factors for homelessness among patients admitted to a state hospital. Am. J. Psychiatry (1991) 148:1659-1664.
   PubMed Web of Science ®Google Scholar
• THORNICROFT G, TANSELLA M, BECKER T et al.: The personal impact of schizophrenia in Europe. Schizophr. Res. (2004) 69(2-3):125-132.
   PubMed Web of Science ®Google Scholar
• WYATT RJ, HENTER I, LEARY MC, TAYLOR E: An economic evaluation of schizophrenia – 1991. Social Psychiatry & Psychiatric Epidemiology (1995) 30(5):196-205.
   PubMed Web of Science ®Google Scholar
• GARDNER DM, BALDESSARINI RJ, WARAICH P: Modern antipsychotic drugs: a critical overview. CMAJ Can. Med. Assoc. J. (2005) 172(13):1703-1711.
   PubMed Web of Science ®Google Scholar
• JANICAK PG, DAVIS JM, PRESKORN SH, AYD FJ: Principles and Practice of Psychopharmacotherapy. Williams and Wilkins, Baltimore, MD. (1993):93-177.
   Google Scholar
• CAMPBELL M, YOUNG PI, BATEMAN DN, SMITH JM, THOMAS SH: The use of atypical antipsychotics in the management of schizophrenia. Br. J. Clin. Pharmacol. (1999) 47(1):13-22.
   PubMed Web of Science ®Google Scholar
• SCHOOLER NR: Relapse and rehospitalization: comparing oral and depot antipsychotics. J. Clin. Psychiatry (2003) 64(Suppl. 16):14-17.
   PubMed Web of Science ®Google Scholar
• ALMOND S, KNAPP M, FRANCOIS C, TOUMI M, BRUGHA T: Relapse in schizophrenia: costs, clinical outcomes and quality of life. Br. J. Psychiatry (2004) 184:346-345.
   PubMed Web of Science ®Google Scholar
• TORREY WC, DRAKE RE, DIXON L et al.: Implementing evidence-based practices for persons with severe mental illnesses. Psychiatr. Serv. (2001) 52(1):45-50.
   PubMed Web of Science ®Google Scholar
• LIBERMAN RP, KOPELOWICZ A: Recovery from schizophrenia: a concept in search of research. Psychiatr. Serv. (2005) 56(6):735-742.
   PubMed Web of Science ®Google Scholar
• MARSHALL M, LOCKWOOD A: Assertive community treatment for people with severe mental disorders. Cochrane Database Syst. Rev. (2006) 1:CD001089.
   Google Scholar
• BOND GR, BECKER DR, DRAKE RE et al.: Implementing supported employment as an evidence-based practice. Psychiatr. Serv. (2001) 52(3):313-322.
   PubMed Web of Science ®Google Scholar
• DIXON L, MCFARLANE WR, LEFLEY H et al.: Evidence-based practices for services to families of people with psychiatric disabilities. Psychiatr. Serv. (2001) 52(7):903-910.
   PubMed Web of Science ®Google Scholar
• MUESER KT, CORRIGAN PW, HILTON DW et al.: Illness management and recovery: a review of the research. Psychiatr. Serv. (2002) 53(10):1272-1284.
   PubMed Web of Science ®Google Scholar
• DRAKE RE, ESSOCK SM, SHANER A et al.: Implementing dual diagnosis services for clients with severe mental illness. Psychiatr. Serv. (2001) 52(4):469-476.
   PubMed Web of Science ®Google Scholar
• LEHMAN AF, STEINWACHS DM: Patterns of usual care for schizophrenia: initial results from the Schizophrenia Patient Outcomes Research Team (PORT) Client Survey. Schizophr. Bull. (1998) 24:11-20.
   PubMed Web of Science ®Google Scholar
• ANDERSON J, ADAMS C: Family interventions in schizophrenia: an effective but underused treatment. Br. Med. J. (1996) 313:505-506.
   PubMedGoogle Scholar
• KANE J, HONINGFELD G, SINGER J, MELTZER H: Clozapine for the treatment resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch. Gen. Psychiatry (1989) 45:789-796.
   Google Scholar
• ESSOCK SM, HARGREAVES WA, COVELL NH et al.: Clozapine’s effectiveness for patients in state hospitals: results from a randomized study. Psychopharm Bull. (1996) 32:683-697.
   PubMedGoogle Scholar
• DAVIS JM, CHEN N, GLICK ID: A meta-analysis of the efficacy of second-generation antipsychotics. Arch. Gen. Psychiatry (2003) 60:553-564.
   PubMed Web of Science ®Google Scholar
• LEUCHT S, WAHLBECK K, HAMANN J, KISSLING W: New generation antipsychotics versus low potency conventional antipsychotics: a systematic review and meta-analysis. Lancet (2003) 361:1581-1589.
   PubMed Web of Science ®Google Scholar
• MILLER AL, HALL CS, BUCHANAN RWM et al. The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update. J. Clin. Psychiatry (2004) 65(4):500-508.
   PubMed Web of Science ®Google Scholar
• LITTRELL RA: NASMHPD Medical Directors Best Practice Symposium. October 2000, Philadelphia, PA.
   Google Scholar
• HARGREAVES WA, SHUMWAY M, HU TW et al.: Cost Outcome Methods for Mental Health. San Diego, Academic Press (1998).
   Google Scholar
• CHOUINARD G, ALBRIGHT PS: Economic and health state utility determinations for schizophrenic patients treated with risperidone or haloperidol. J. Clin. Psychopharmacol. (1997) 17(4):298-307.
   PubMed Web of Science ®Google Scholar
• TOLLEY G, KENKEL D, FABIAN R: Valuing Health for policy: An Economic Approach. Chicago: University of Chicago Press (1994).
   Google Scholar
• LUCHINS DJ, CHIRIAC I, HANRAHAN P et al.: Allocating funds for medications and psychosocial interventions: How consumers would divide the pie. Psychiatr. Serv. (2005) 56:799-801.
   PubMedGoogle Scholar
• HAMILTON SH, REVICKI DA, EDGELL ET, GENDUSO LA, TOLLEFSON G: Clinical and economic outcomes of olanzapine compared with haloperidol for schizophrenia. Results from a randomised clinical trial. Pharmacoeconomics (1999) 15(5):469-480.
   PubMed Web of Science ®Google Scholar
• TUNIS SL, JOHNSTONE BM, GIBSON PJ, LOOSBROCK DL, DULISSE BK: Changes in perceived health and functioning as a cost-effectiveness measure for olanzapine versus haloperidol treatment of schizophrenia. J. Clin. Psychiatry (1999) 60(Suppl. 19):38-45; discussion 46.
   PubMedGoogle Scholar
• JERRELL JM: Cost-effectiveness of risperidone, olanzapine, and conventional antipsychotic medications. Schizophr. Bull. (2002) 28(4):589-605.
   PubMed Web of Science ®Google Scholar
• ROSENHECK R, PERLICK D, BINGHAM S: Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial. JAMA (2003) 290(20):2693-2702.
   PubMed Web of Science ®Google Scholar
• MAHMOUD R: RIS-USA-56C Post Study Investigators’ Meeting. Rancho Mirage, California (23 – 25 January 1998).
   Google Scholar
• MAHMOUD R, ENGELHART LM, JANAGAP DD, OSTER G, OLLENDORF D: Risperidone versus conventional antipsyhcotics for schizophrenia and schizoaffective disorder: Symptoms, quality of life and resource use under customary clinical care. Clin. Drug Investig. (2004) 24(5):275-286.
   PubMed Web of Science ®Google Scholar
• TOLLEFSON GD, BEASLEY CM, TRAN PV et al.: Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am. J. Psychiatry (1997) 154(4):457-465.
   PubMed Web of Science ®Google Scholar
• DUGGAN L, FENTON M, RATHBONE J, DARDENNES R, EL-DOSOKY A, INDRAN S: Olanzapine for schizophrenia. Cochrane Database Syst. Rev. (2006) 1:CD001359.
   Google Scholar
• LAMB HR, WEINBERGER LE: The shift of psychiatric inpatient care from hospitals to jails and prisons. J. Am. Acad. Psychiatry Law (2005) 33:529-534.
   PubMed Web of Science ®Google Scholar
• WEISBROD BA. Benefit-cost analysis of a controlled experiment: treating the mentally ill. Journal of Human Resources (1981) 16(4):523-548.
   PubMedGoogle Scholar